SEC F	Form 4
-------	--------

Stock Option

Buy)

(Right to

\$3.88

Explanation of Responses:

02/19/2019

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

					0	or Sect	ion 30(h)	of the	Investment	Con	npany Act	of 19	940						
1. Name and Address of Reporting Person [*] van Elsas Andrea					2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ADRO]									elationship o ck all applica Director	,				
														Officer	give title		Other (s		
						3. Date of Earliest Transaction (Month/Day/Year)									below)			below)	peeny
(Last) (First) (Middle)					02	02/19/2019									Chief Scientific Officer				
KLOOSTERSTRAAT 9																			
(Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
OSS	P	7	5349 AB											2	X Form filed by One Reporting Person				
(City)	(S	itate)	(Zip)												Form fil Person	ed by Mor	e than	One Report	ing
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/E				/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) Securities Beneficia Owned Fo	5. Amount of Securities Beneficially Owned Following		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount		(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)			instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	ate, Ti C	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	Date	r) of Sec Under Deriva		Title and Amount of Securities Underlying Derivative Security Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	ode	v	(A)		Date Exercisable		xpiration ate	Title	O N	mount r umber f Shares		(Instr. 4)	.,		

(1)

Common

Stock

400,000

/s/ Jennifer Lew, Attorney-in-

<u>Fact for Andrea van Elsas</u> ** Signature of Reporting Person

\$0.00

400,000

02/21/2019

Date

D

02/18/2029

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

400,000

A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

1. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 19, 2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.